Cancer

Chinese researchers divulge new GSPT1 degraders for cancer

May 31, 2023

Researchers at Fudan University and Shanghai Meizer Pharmaceuticals Co. Ltd. have...

Today's news in brief

BioWorld

BioWorld briefs for May 11, 2026.

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

Hantavirus is ‘sentinel’ more than acute pandemic threat

BioWorld

News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...

Infensa Bioscience identifies new ASIC blockers

BioWorld Science

Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.

Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst

BioWorld

Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...

Items Tagged with 'Shanghai Meizer Pharmaceuticals Co. Ltd.'

ARTICLES

Chinese researchers divulge new GSPT1 degraders for cancer

Today's news in brief

First measles treatment advances as vaccination rates drop

Hantavirus is ‘sentinel’ more than acute pandemic threat

Infensa Bioscience identifies new ASIC blockers

Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst